person · Reporting owner
Pacelli Steven Robert
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Managing Director Dexcom V | November 24, 2023 | November 27, 2023 |
| ProSomnus, Inc.OSA · Entity 94197 | Director | December 06, 2022 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date November 24, 2023 · Filed November 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,775 |
Reported balance
After 2023-11-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-24 · Sale · Disposed 411 · Balance 124,775 F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
ProSomnus, Inc.
Report date December 06, 2022 · Filed February 16, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,200 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 18,200 F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2023 Filed Nov 27, 2023 21:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 411 | $110.80 | $45,538.80 |
DisclosureSEC source: 0001093557-23-000234 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,775 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 23:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 411 | $85.75 | $35,243.25 |
DisclosureSEC source: 0001093557-23-000209 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,186 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| September 22, 2023 Filed Sep 22, 2023 22:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 411 | $88.40 | $36,332.40 |
DisclosureSEC source: 0001093557-23-000205 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,597 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| August 23, 2023 Filed Aug 23, 2023 21:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 411 | $107.03 | $43,989.33 |
DisclosureSEC source: 0001093557-23-000184 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,008 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 21:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $130.58 | $53,798.96 |
DisclosureSEC source: 0001093557-23-000167 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,419 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 20:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,031 | $136.00 | $684,216.00 |
DisclosureSEC source: 0001093557-23-000165 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,831 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $125.92 | $51,879.04 |
DisclosureSEC source: 0001093557-23-000159 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,862 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| May 23, 2023 Filed May 23, 2023 23:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $118.65 | $48,883.80 |
DisclosureSEC source: 0001093557-23-000147 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,274 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,031 | $126.00 | $633,906.00 |
DisclosureSEC source: 0001093557-23-000120 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,686 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $124.68 | $51,368.16 |
DisclosureSEC source: 0001093557-23-000114 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,717 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 21:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,442 | $116.40 | $633,448.80 |
DisclosureSEC source: 0001093557-23-000091 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,129 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,405 | $111.40 | $267,914.60 |
DisclosureSEC source: 0001093557-23-000080 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,571 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,990 | $111.40 | $667,280.01 |
DisclosureSEC source: 0001093557-23-000080 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,976 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,274 | $111.40 | $364,720.33 |
DisclosureSEC source: 0001093557-23-000080 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,966 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 20:58 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 18,776 | $0.00 | $18.78 |
DisclosureSEC source: 0001093557-23-000052 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,240 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| February 23, 2023 Filed Feb 23, 2023 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $111.64 | $45,995.68 |
DisclosureSEC source: 0001093557-23-000028 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,464 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 19:33 UTC | ProSomnus, Inc. OSA · Entity 94197 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001474506-23-000044 · primary_doc.xml · derivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · derivative.expiration_date: Stock options vest annually over 4 years at 25% on each anniversary year. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 21:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $107.86 | $44,438.32 |
DisclosureSEC source: 0001093557-23-000011 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,876 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 21:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 412 | $112.57 | $46,378.84 |
DisclosureSEC source: 0001093557-22-000183 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,288 F1 · shares: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 21:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $84.21 | $84,210.00 |
DisclosureSEC source: 0001093557-22-000153 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,700 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 22:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $83.07 | $83,070.00 |
DisclosureSEC source: 0001093557-22-000132 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,700 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $72.55 | $72,550.00 |
DisclosureSEC source: 0001093557-22-000130 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,700 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $296.33 | $74,082.50 |
DisclosureSEC source: 0001093557-22-000124 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,175 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:47 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $439.94 | $109,985.00 |
DisclosureSEC source: 0001093557-22-000092 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,425 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $459.98 | $114,995.00 |
DisclosureSEC source: 0001093557-22-000067 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,675 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,180 | $406.06 | $479,146.91 |
DisclosureSEC source: 0001093557-22-000050 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,925 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 932 | $406.06 | $378,444.84 |
DisclosureSEC source: 0001093557-22-000050 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,105 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,317 | $406.06 | $534,776.67 |
DisclosureSEC source: 0001093557-22-000050 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,037 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 4,984 | $0.00 | $4.98 |
DisclosureSEC source: 0001093557-22-000050 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,354 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $394.33 | $98,582.50 |
DisclosureSEC source: 0001093557-22-000020 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,370 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $416.77 | $104,192.50 |
DisclosureSEC source: 0001093557-22-000005 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,620 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $573.91 | $143,477.50 |
DisclosureSEC source: 0001093557-21-000295 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,870 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 00:44 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000276 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,120 F1 · shares: The transaction represents a gift by the Reporting Person of 5,459 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 23:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $612.26 | $153,065.00 |
DisclosureSEC source: 0001093557-21-000260 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,579 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $570.00 | $142,500.00 |
DisclosureSEC source: 0001093557-21-000241 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,829 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $576.58 | $144,144.00 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 8 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,079 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $576.480 to $576.635. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,312 | $575.74 | $755,375.60 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 7 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,329 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $575.28 to $576.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 554 | $574.90 | $318,493.49 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $574.28 to $575.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,744 | $573.60 | $1,000,359.10 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,195 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $573.18 to $574.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 983 | $572.60 | $562,863.54 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,939 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $572.150 to $573.055. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,142 | $571.50 | $652,655.51 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,922 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $571.03 to $572.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 438 | $570.42 | $249,846.06 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,064 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $570.01 to $570.85. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 320 | $569.63 | $182,282.21 |
DisclosureSEC source: 0001093557-21-000233 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,502 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $569.01 to $569.69. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 15 | $542.01 | $8,130.13 |
DisclosureSEC source: 0001093557-21-000216 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,822 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,248 | $541.36 | $675,617.28 |
DisclosureSEC source: 0001093557-21-000216 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,837 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 604 | $517.96 | $312,846.15 |
DisclosureSEC source: 0001093557-21-000197 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,085 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $517.54 to $517.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 96 | $516.17 | $49,552.32 |
DisclosureSEC source: 0001093557-21-000197 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,689 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 122 | $515.14 | $62,846.98 |
DisclosureSEC source: 0001093557-21-000197 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,785 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $514.745 to $515.340. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 256 | $513.41 | $131,432.83 |
DisclosureSEC source: 0001093557-21-000197 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,907 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $513.18 to $513.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:03 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 800 | $452.65 | $362,120.00 |
DisclosureSEC source: 0001093557-21-000182 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,163 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.